



POLYCLONAL ANTI-RAT ACETYLSEROTONIN METHYLTRANSFERASE (ASMT)

SUMMARY

The Eunice Kennedy Shriver National Institute of Child Health and Human Development seeks parties to non-exclusively license polyclonal anti-rat acetylserotonin methyltransferase (ASMT).

REFERENCE NUMBER

E-059-2016

PRODUCT TYPE

- Research Materials

COLLABORATION OPPORTUNITY

This invention is available for licensing.

CONTACT

Martha Lubet

NICHHD - Eunice Kennedy Shriver National Institute on Child Health and Human Development
240-276-5508

Martha.Lubet@nih.gov

DESCRIPTION OF TECHNOLOGY

Rabbits were immunized with peptide corresponding to residues 308-321 of rat ASMT. Human ASMT and ASMT of other species do not have this sequence and the anti-ASMT would be specific for the rat ASMT. Antibody specificity to the peptide used as immunogen was verified by blocking the antibody's reactivity with pineal gland tissue with the immunogen. In western blot, the rabbit anti-ASMT serum only reacts with pineal gland and retinal tissue and identifies a band corresponding to the size of the predicted protein. In immunohistochemistry, the reagents only identify pinealocytes.

POTENTIAL COMMERCIAL APPLICATIONS

- Useful in detecting rat acetylserotonin methyltransferase in immunological assays, including western blot and immunohistochemistry.

INVENTOR(S)

David C. Klein (NICHD, retired), [Steven L. Coon](#) (NICHD)

DEVELOPMENT STAGE

- Discovery (Lead Identification)



PUBLICATIONS

Rath MF, Coon SL, Amaral FG, Weller JL, Møller M, Klein DC. *Endocrinology*. 2016 Mar 7:en20151888.
[Epub ahead of print]

PATENT STATUS

- **Not Patented:** Research Material: The NICHD will not seek patent protection for this invention.

THERAPEUTIC AREA

- Cancer/Neoplasm